Related references
Note: Only part of the references are listed.Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study
Maximilian Stahl et al.
LEUKEMIA (2020)
Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).
Tapan M. Kadia et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Christoph Roellig et al.
BLOOD (2020)
Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis
Jan P. Bewersdorf et al.
TRANSFUSION (2020)
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
Courtney D. DiNardo et al.
LANCET HAEMATOLOGY (2020)
Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
Chi Young Ok et al.
HAEMATOLOGICA (2019)
Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients
Feng-Ming Tien et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large US web-based survey*
Maximilian Stahl et al.
LEUKEMIA & LYMPHOMA (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Genetic and epigenetic heterogeneity in acute myeloid leukemia
Sheng Li et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2016)
Leukostasis in adult acute hyperleukocytic leukemia: a clinician's digest
Alaa M. Ali et al.
HEMATOLOGICAL ONCOLOGY (2016)
Mutations in AML: prognostic and therapeutic implications
Courtney D. DiNardo et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
How I treat hyperleukocytosis in acute myeloid leukemia
Christoph Roellig et al.
BLOOD (2015)
Toward Individualized Therapy in Acute Myeloid Leukemia A Contemporary Review
Tapan M. Kadia et al.
JAMA ONCOLOGY (2015)
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring
Rajyalakshmi Luthra et al.
HAEMATOLOGICA (2014)
Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: A systematic review and meta-analysis
Sapna Oberoi et al.
LEUKEMIA RESEARCH (2014)
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia
Sarah Bertoli et al.
BLOOD (2013)
Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients
Mikako Warren et al.
MODERN PATHOLOGY (2012)
Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome
Gudrun Goehring et al.
BLOOD (2010)
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
Mikkael A. Sekeres et al.
BLOOD (2009)
Outcome of hyperleukocytic adult acute myeloid leukaemia: A single-center retrospective study and review of literature
Laura Marbello et al.
LEUKEMIA RESEARCH (2008)
Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia
M. J. Greenwood et al.
LEUKEMIA & LYMPHOMA (2006)
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long term survival
FJ Giles et al.
LEUKEMIA & LYMPHOMA (2001)
Share Paper
